The US FDA has approved milsaperidone, an atypical antipsychotic indicated for the treatment of schizophrenia in adults and the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Clinical evidence In a clinical trial, milsaperidone demonstrated bioequivalence to iloperidone across the therapeutic dosing spectrum, with efficacy and safety.
Dosage and administration Available in tablet form Administer milsaperidone orally twice daily with or without food Titrate milsaperidone to reduce the risk of orthostatic hypotension After the titration, recommended maintenance dosage for: Schizophrenia is 6 to 12 mg twice daily Bipolar mania is 12 mg twice daily Contraindications Hypersensitivity Warnings and precautions Cerebrovascular adverse reactions in elderly patients with dementia Qtc interval prolongatio Neuroleptic malignant syndrome Tardive dyskinesia…
